

Financial news for SPRO dated on 2020-06-02: 71 Biggest Movers From Yesterday

Financial news for SPRO dated on 2020-06-01: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for SPRO dated on 2020-05-11: HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Raises Price Target to \$28

Financial news for SPRO dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for SPRO dated on 2020-05-05: Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

Financial news for SPRO dated on 2020-04-29: 82 Biggest Movers From Yesterday

Financial news for SPRO dated on 2020-04-28: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SPRO dated on 2020-04-28: 96 Biggest Movers From Yesterday

Financial news for SPRO dated on 2020-04-27: 72 Stocks Moving In Monday's Mid-Day Session

Financial news for SPRO dated on 2020-04-22: 52 Biggest Movers From Yesterday

Financial news for SPRO dated on 2020-04-21: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SPRO dated on 2020-03-18: 130 Biggest Movers From Yesterday

Financial news for SPRO dated on 2020-03-17: Stifel Maintains Buy on Spero Therapeutics, Lowers Price Target to \$21

Financial news for SPRO dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for SPRO dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for SPRO dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for SPRO dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for SPRO dated on 2020-03-11: Spero Therapeutics Reports Receives FDA Orphan Drug Designation For SPR720 For Treatment Of Nontuberculous Mycobacterial Infection

Financial news for SPRO dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for SPRO dated on 2020-02-05: Spero Therapeutics Reports Exercise Of \$15.9M Option By BARDA For Tebipenem HBr Development

Financial news for SPRO dated on 2020-01-30: Spero Therapeutics To Raise \$30M Via Rights Offering Of Convertible Shares

Financial news for SPRO dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for SPRO dated on 2020-01-13: Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR206 Suggesting It Is Well-Tolerated At Doses Within Therapeutic Range For Target And Plans To Advance Program With Alliance Partners Everest Medicines And The Department Of Defense

Financial news for SPRO dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for SPRO dated on 2019-12-04: Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR720; Says First Indication Of Human Safety And PK Profiles Supports Advancement Of Program To Phase 2a PProof-Of-Concept Trial

Financial news for SPRO dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for SPRO dated on 2019-11-05: H.C. Wainwright Maintains Buy on Spero Therapeutics, Raises Price Target to \$35

Financial news for SPRO dated on 2019-11-04: Spero Therapeutics Q3 EPS \$(0.95) Misses \$(0.85) Estimate, Sales \$4.643M Beat \$2.45M Estimate

Financial news for SPRO dated on 2019-10-03: Spero Therapeutics Shares Up ~4-5% Over Last 15 Mins As Hearing Janney Raised Price Target On Stock To New Street High Of \$31; BZ NOTE: Represents Potential Upside Of 187%

Financial news for SPRO dated on 2019-10-03: Spero Therapeutics Highlights Recommendation To Continue Phase 3 Trial Of SPR994 As Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial

Financial news for SPRO dated on 2019-09-09: Benzinga's Top Upgrades, Downgrades For September 9, 2019

Financial news for SPRO dated on 2019-09-09: Janney Capital Initiates Coverage On Spero Therapeutics with Buy Rating

Financial news for SPRO dated on 2019-09-06: Spero Therapeutics 8-K Shows CFO Joel Sendek Resigned; Co. Has Commenced Search For Replacement

Financial news for SPRO dated on 2019-09-04: H.C. Wainwright Assumes Spero Therapeutics at Buy, Announces \$28 Price Target

Financial news for SPRO dated on 2019-08-08: Spero Therapeutics Q2 EPS \$(0.74) Misses \$(0.65) Estimate, Sales \$2.156M Miss \$5.05M Estimate

Financial news for SPRO dated on 2019-07-16: Spero Therapeutics Announces \$5.9M Award From US Department Of Defense To Further Clinical Development of SPR206

Financial news for SPRO dated on 2019-06-28: 62 Biggest Movers From Yesterday

Financial news for SPRO dated on 2019-06-27: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for SPRO dated on 2019-06-13: Spero Reports \$10M Registered Direct Offering Of Common Stock

Financial news for SPRO dated on 2019-04-08: Spero Therapeutics Highlights SPR994 Data At 29th European Congress Of Clinical Microbiology And Infectious Diseases

Financial news for SPRO dated on 2019-03-29: Spero Therapeutics Reports Received FDA Fast Track Designation For SPR994 For Treatment Of Complicated Urinary Tract Infections, Acute Pyelonephritis

Financial news for SPRO dated on 2019-03-14: Spero Therapeutics Q4 EPS \$(0.60) Up From \$(1.59) YoY

Financial news for SPRO dated on 2019-02-26: Spero Therapeutics Reports Received QIDP Designation From FDA For Development OF SPR720

Financial news for SPRO dated on 2019-02-04: Spero Therapeutics Announces the FDA Has Accepted its Investigational New Drug Application for SPR994

Financial news for SPRO dated on 2019-01-29: Spero Therapeutics Announces Initiation Of SPR720 Phase 1 Clinical Trial For Non-Tuberculous Mycobacterial Infections

Financial news for SPRO dated on 2019-01-24: Shares of biotech companies with ties to the lung cancer space are trading higher after Bristol-Myers Squibb withdrew its regulatory application for its lung cancer combo drug.

Financial news for SPRO dated on 2019-01-08: The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

Financial news for SPRO dated on 2019-01-07: Spero Therapeutics Signs License Agreement With Everest Medicines To Develop, Manufacture And Commercialize SPR206 In Asia, With Option For SPR741 Rights, Initiates SPR206 Phase 1 Clinical Trial ; Co. To Receive \$2M Upfront And Up To \$59.5M In Milestones

Financial news for SPRO dated on 2019-01-07: Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in CUTI

Financial news for SPRO dated on 2018-12-28: 50 Biggest Movers From Yesterday

Financial news for SPRO dated on 2018-12-19: Stocks Which Set New 52-Week Low

Yesterday, Tues., Dec. 18, 2018

Financial news for SPRO dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for SPRO dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for SPRO dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for SPRO dated on 2018-11-05: UPDATE: Spero Therapeutics Plans To Initiate Phase 1 Trial Of SPR720 In Early 2019

Financial news for SPRO dated on 2018-11-05: Spero Therapeutics Reports Results From SPR720 IND-Enabling Studies: Showed Candidate Achieved 'wide therapeutic margins and activity versus multiple clinically important species of non-tuberculous mycobacteria'

Financial news for SPRO dated on 2018-10-17: The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Financial news for SPRO dated on 2018-10-17: 48 Biggest Movers From Yesterday

Financial news for SPRO dated on 2018-10-16: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SPRO dated on 2018-10-16: Mid-Day Market Update: Dow Rises Over 350 Points; Hanwha Q CELLS Shares Spike Higher

Financial news for SPRO dated on 2018-10-16: 10 Biggest Price Target Changes For Tuesday

Financial news for SPRO dated on 2018-10-16: Benzinga's Top Upgrades, Downgrades For October 16, 2018

Financial news for SPRO dated on 2018-10-16: Bank of America Downgrades Spero Therapeutics to Underperform, Lowers Price Target to \$9

Financial news for SPRO dated on 2018-10-11: Spero Therapeutics Receives Qualified Infectious Disease Product Designation From FDA FDA For The Development Of SPR206

Financial news for SPRO dated on 2018-09-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for SPRO dated on 2018-09-28: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results

Financial news for SPRO dated on 2018-09-27: Spero Announces "Positive" Phase 1 SAD/MAD Final Results, Showing A Favorable Safety Profile, Expects To Advance Into a Pivotal Phase 3 Clinical Trial By Year-End

Financial news for SPRO dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for SPRO dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for SPRO dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for SPRO dated on 2018-08-09: Amtech Sees Q4 Sales \$26-\$28M vs \$40M Est.

Financial news for SPRO dated on 2018-08-09: Spero Therapeutics Q2 EPS \$(0.69) vs \$(36.21) In Prior Year Period, Sales \$463K vs \$249K In Prior Year Period

Financial news for SPRO dated on 2018-07-17: Spero Therapeutics Amended 13D Filing From GlaxoSmithKline Shows Cut Stake From 13.3% As Of Nov. 16, 2017 To 10.7%

Financial news for SPRO dated on 2018-07-16: Spero Therapeutics Awarded \$15.7M From the Biomedical Advanced Research and Development Authority

Financial news for SPRO dated on 2018-07-12: Spero Therapeutics Prices 3.78M Share Public Offering of Common Stock @\$12.50/Share

Financial news for SPRO dated on 2018-07-11: 41 Biggest Movers From Yesterday

Financial news for SPRO dated on 2018-07-10: Mid-Afternoon Market Update: OncoCyte

Surges Following Positive DetermaVu Study Results; IsoRay Shares Drop

Financial news for SPRO dated on 2018-07-10: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SPRO dated on 2018-07-10: Mid-Day Market Update: Dow Rises Over 150 Points; Spero Therapeutics Shares Plunge

Financial news for SPRO dated on 2018-07-10: Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Expectations

Financial news for SPRO dated on 2018-07-10: 7 Stocks To Watch For July 10, 2018

Financial news for SPRO dated on 2018-07-09: Spero Therapeutics Files For 4.5M Share Common Stock Offering

Financial news for SPRO dated on 2018-07-09: Spero Says Phase 1 Clinical Data Shows SPR994 To Be Well Tolerated At Single And Multiple Ascending Doses

Financial news for SPRO dated on 2018-06-20: 48 Biggest Movers From Yesterday

Financial news for SPRO dated on 2018-06-19: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SPRO dated on 2018-05-23: UPDATE: Spero Therapeutics Reports SPR206 IND-Enabling Studies Showed Potential For Wide Therapeutic Margins, Broad Antimicrobial Spectrum As Single Agent

Financial news for SPRO dated on 2018-05-23: Spero Therapeutics Reports Phase 1b Data For SPR741 Study Showed Pharmacokinetic Compatibility, Tolerability When Co-Administered With B-Lactam Antibiotics

Financial news for SPRO dated on 2018-05-19: Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Financial news for SPRO dated on 2018-05-11: Benzinga's Top Upgrades, Downgrades For May 11, 2018

Financial news for SPRO dated on 2018-05-11: H.C. Wainwright Initiates Coverage On Spero Therapeutics, Inc. - Common Stock with Buy Rating, Announces \$28 Price Target

Financial news for SPRO dated on 2018-05-10: Spero Therapeutics, Inc. - Common Stock Q1 EPS \$(0.74) Up From \$(21.60) YoY, Sales \$1.153M Up From \$140K YoY

Financial news for SPRO dated on 2018-05-01: Secondary Offering Lockup Expirations Today For: Allena Pharma, Evoqua Water Technologies, Spero Therapeutics, and Funko

Financial news for SPRO dated on 2018-04-16: 40 Biggest Movers From Friday

Financial news for SPRO dated on 2018-04-02: Spero Therapeutics Q4 EPS \$(1.59) Misses \$(1.35) Est., Grant Sales \$993K Beats \$330K Est.

Financial news for SPRO dated on 2018-03-14: Nano, Micro-Cap Pharma/Biotech Stocks Up On No Formal News: Syndax Pharma Shares Up 19.2%, Avenue Therapeutics Up 16.1%, Kazia Therapeutics Up 9.9%, Spero Therapeutics Up 6.4%

Financial news for SPRO dated on 2018-02-09: Benzinga's Top Upgrades, Downgrades For February 9, 2018

Financial news for SPRO dated on 2018-02-09: Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces \$27.00 Price Target

Financial news for SPRO dated on 2017-12-14: Spero Therapeutics Reports Q3 EPS \$(36.02) vs \$(23.23) In Same Qtr. Last Year, Sales \$597K vs \$200K Est.

Financial news for SPRO dated on 2017-11-27: Benzinga's Top Upgrades, Downgrades For November 27, 2017

Financial news for SPRO dated on 2017-11-27: Bank of America Initiates Coverage On Spero Therapeutics with Neutral Rating, Announces \$16.00 Price Target

Financial news for SPRO dated on 2017-11-27: Cowen & Co. Initiates Coverage On Spero Therapeutics with Outperform Rating

Financial news for SPRO dated on 2017-11-27: Stifel Nicolaus Initiates Coverage On Spero Therapeutics with Buy Rating, Announces \$26.00 Price Target

Financial news for SPRO dated on 2017-11-04: Funko Flops As IPO Market Cools Once Again

Financial news for SPRO dated on 2017-11-02: Spero Therapeutics Shares Open For Trade At \$13.25; IPO Priced At \$14/Share

Financial news for SPRO dated on 2017-11-02: IPOs Expected Evoqua Water Technologies (AQUA), Funko (FNKO), Allena Pharmaceuticals (ALNA), Energy Hunter Resources (EHR), and Spero Therapeutics (SPRO)

Financial news for SPRO dated on 2017-11-02: IPOS for Thursday November 2: Evoqua Water Technologies, Funko, Allena Pharmaceuticals, Spero Therapeutics

Financial news for SPRO dated on 2015-11-05: SmartPros Reports Inline Q3 Loss \$0.06, Revs \$2.79M, no estimate

Financial news for SPRO dated on 2015-10-22: Benzinga's M&A Chatter for Thursday October 22, 2015

Financial news for SPRO dated on 2015-10-22: Stocks Hitting 52-Week Highs

Financial news for SPRO dated on 2015-10-22: Morning Market Gainers

Financial news for SPRO dated on 2015-10-22: Shares of SmartPros to Resume Trade at 8:30 a.m. EDT

Financial news for SPRO dated on 2015-10-22: Graham Holding's Kaplan Acquires SmartPros For ~\$16.9M Cash, 3.57/Share

Financial news for SPRO dated on 2015-10-22: SmartPros Shares Halted-News Pending

Financial news for SPRO dated on 2015-08-06: SmartPros Reports Q2 EPS \$0.10 vs. Prior Year Quarter \$(0.05), Rev. \$3.65M vs. Est. \$3.69M

Financial news for SPRO dated on 2015-05-05: SmartPro Reports Q1 EPS Loss \$0.07, Sales \$2.71M

Financial news for SPRO dated on 2015-03-05: SmartPros Reports Q4 EPS -\$0.35, Sales \$13.5M, No Estimates Available

Financial news for SPRO dated on 2015-02-18: Stocks Hitting 52-Week Lows

Financial news for SPRO dated on 2015-01-13: SmartPros' Skye Multimedia Sells Certain Assets

Financial news for SPRO dated on 2014-08-07: SmartPros Q2 Revenue \$4M, EPS -\$0.05

Financial news for SPRO dated on 2014-06-16: SmartPros Announces Staffing Reductions And Plans to Close Verticals of Business That Are Not Profitable

Financial news for SPRO dated on 2013-11-27: Morning Market Losers

Financial news for SPRO dated on 2013-11-07: SmartPros Ltd. Reports Q3 EPS of \$0.00; Revenue of \$3.76M

Financial news for SPRO dated on 2013-09-18: Morning Market Losers

Financial news for SPRO dated on 2013-08-06: SmartPros Ltd. Reports Q2 EPS of \$0.01; Revenue of \$4.50M, Up 7% YOY

Financial news for SPRO dated on 2013-07-08: Morning Market Movers

Financial news for SPRO dated on 2013-03-07: SmartPros Raises Qtr. Dividend from \$0.0125 to \$0.015/Share

Financial news for SPRO dated on 2013-01-09: Morning Market Movers

Financial news for SPRO dated on 2013-01-08: Morning Market Movers

Financial news for SPRO dated on 2012-08-07: SmartPros Reports Q2 EPS \$-0.02; Revenues \$4.2M

Financial news for SPRO dated on 2012-06-14: SmartPros Acquires Certain Assets of Global Collaboration Partners LLC

Financial news for SPRO dated on 2011-05-31: NASDAQ Stocks Hitting 52-Week Lows